These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 32324678

  • 1. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome.
    Campbell JP, Zierold C, Rode AM, Blocki FA, Vaughn BP.
    J Clin Gastroenterol; 2021 Mar 01; 55(3):239-243. PubMed ID: 32324678
    [Abstract] [Full Text] [Related]

  • 2. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P.
    Inflamm Bowel Dis; 2012 Dec 01; 18(12):2218-24. PubMed ID: 22344983
    [Abstract] [Full Text] [Related]

  • 3. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, Clar C, Johnston R.
    Health Technol Assess; 2013 Nov 01; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [Abstract] [Full Text] [Related]

  • 4. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH, Chou JW, Chen SM, Tsai MC, Sun YS, Lin CC, Lin CP.
    Mol Med Rep; 2014 Jul 01; 10(1):522-6. PubMed ID: 24788223
    [Abstract] [Full Text] [Related]

  • 5. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
    Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R.
    Inflamm Bowel Dis; 2007 Nov 01; 13(11):1374-8. PubMed ID: 17577247
    [Abstract] [Full Text] [Related]

  • 6. Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study.
    David LE, Surdea-Blaga T, Dumitrascu DL.
    Sao Paulo Med J; 2015 Nov 01; 133(4):343-9. PubMed ID: 26039537
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
    Yang Z, Clark N, Park KT.
    Clin Gastroenterol Hepatol; 2014 Feb 01; 12(2):253-62.e2. PubMed ID: 23883663
    [Abstract] [Full Text] [Related]

  • 8. Role of Calprotectin, IL-6, and CRP in Distinguishing Between Inflammatory Bowel Disease and Diarrhea Predominant Irritable Bowel Syndrome.
    Huong BT, Hien NM, Dung NT, Quang DM, Vinh NT, Tu TT, Chi TK, Phuong LB, Nhan NT.
    Med Arch; 2024 Feb 01; 78(2):105-111. PubMed ID: 38566874
    [Abstract] [Full Text] [Related]

  • 9. Clinical Significance of Faecal Calprotectin in Differentiating Inflammatory Bowel Disease from Irritable Bowel Syndrome.
    Chowdhury MFK, Ghosh CK, Miah MSA, Uddin MA, Rassell M, Rashid MH, Pal AK, Mahabub-Uz-Zaman K, Saha KP, Miah MAR.
    Mymensingh Med J; 2024 Oct 01; 33(4):1149-1156. PubMed ID: 39351737
    [Abstract] [Full Text] [Related]

  • 10. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
    Oyaert M, Trouvé C, Baert F, De Smet D, Langlois M, Vanpoucke H.
    Clin Chem Lab Med; 2014 Mar 01; 52(3):391-7. PubMed ID: 24114912
    [Abstract] [Full Text] [Related]

  • 11. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Diederen K, Hoekman DR, Hummel TZ, de Meij TG, Koot BG, Tabbers MM, Vlieger AM, Kindermann A, Benninga MA.
    Aliment Pharmacol Ther; 2016 Jul 01; 44(2):181-8. PubMed ID: 27110920
    [Abstract] [Full Text] [Related]

  • 12. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
    Sydora MJ, Sydora BC, Fedorak RN.
    J Crohns Colitis; 2012 Mar 01; 6(2):207-14. PubMed ID: 22325175
    [Abstract] [Full Text] [Related]

  • 13. Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
    Dajti E, Frazzoni L, Iascone V, Secco M, Vestito A, Fuccio L, Eusebi LH, Fusaroli P, Rizzello F, Calabrese C, Gionchetti P, Bazzoli F, Zagari RM.
    Aliment Pharmacol Ther; 2023 Dec 01; 58(11-12):1120-1131. PubMed ID: 37823411
    [Abstract] [Full Text] [Related]

  • 14. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation.
    Mooiweer E, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B.
    Inflamm Bowel Dis; 2014 Feb 01; 20(2):307-14. PubMed ID: 24374878
    [Abstract] [Full Text] [Related]

  • 15. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders.
    Caviglia GP, Pantaleoni S, Touscoz GA, Adriani A, Rosso C, Smedile A, Pellicano R, Astegiano M, Bresso F.
    Scand J Gastroenterol; 2014 Dec 01; 49(12):1419-24. PubMed ID: 25369978
    [Abstract] [Full Text] [Related]

  • 16. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
    Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, Ford AC.
    Clin Gastroenterol Hepatol; 2017 Mar 01; 15(3):376-384.e5. PubMed ID: 27189912
    [Abstract] [Full Text] [Related]

  • 17. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Hoekman DR, Zeevenhooven J, D'Haens GR, Benninga MA.
    Eur J Gastroenterol Hepatol; 2017 Sep 01; 29(9):1086-1090. PubMed ID: 28639969
    [Abstract] [Full Text] [Related]

  • 18. Fecal calprotectin levels in children is more tightly associated with histological than with macroscopic endoscopy findings.
    Hradsky O, Ohem J, Mitrova K, Durilova M, Kotalova R, Nevoral J, Kolho KL, Bronsky J.
    Clin Lab; 2014 Sep 01; 60(12):1993-2000. PubMed ID: 25651733
    [Abstract] [Full Text] [Related]

  • 19. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
    Silberer H, Küppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, Kempf A, Schmidt-Gayk H.
    Clin Lab; 2005 Sep 01; 51(3-4):117-26. PubMed ID: 15819166
    [Abstract] [Full Text] [Related]

  • 20. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D.
    Gut; 2007 Dec 01; 56(12):1706-13. PubMed ID: 17675327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.